文献速递耳科与耳神经小儿耳鼻咽喉

致病性MYO15A变异患者的听力特征与人工耳蜗植入效果:一项多中心观察性研究

Hearing Features and Cochlear Implantation Outcomes in Patients With Pathogenic MYO15A Variants: a Multicenter Observational Study.
PubMed 文献 · Ear Hear · 2021-12-29

该多中心观察性研究纳入31个无关家庭的40例双等位基因MYO15A变异患者,按是否携带N端结构域变异分组,比较纵向听力学数据及人工耳蜗植入后的听觉言语表现。首次听力检查时80.0%患者为重度至极重度感音神经性听力损失,携带至少一个N变异等位基因者听力水平显著优于双等位基因非N变异者,非极重度患者中82.4%呈进展性听力下降,多数植入人工耳蜗者术后听觉言语表现良好。

要点

  • 40例双等位基因MYO15A变异患者中,首次听力检查时32例(80.0%)为重度至极重度感音神经性听力损失。
  • 携带至少一个N变异等位基因者听力水平显著优于双等位基因非N变异者(78.2 ± 23.9 dBHL vs 94.7 ± 22.8 dBHL,p = 0.033)。
  • 非极重度患者中82.4%呈进展性听力下降,平均进展速率6.3 ± 4.8 dBHL/年,与基因型无关。

核心结论

  • 双等位基因致病性MYO15A变异患者的听力特征为重度至极重度感音神经性听力损失、快速听力进展,人工耳蜗植入后效果良好。
  • 作者认为对这些患者应进行定期听力监测以实现早期干预。

研究设计与样本

  • 多中心观察性研究,招募来自31个无关家庭的40例双等位基因MYO15A变异患者。
  • 根据是否携带N端结构域变异(N变异)分组,比较纵向听力学数据及人工耳蜗植入后的听觉言语表现。

主要发现

  • 首次听力检查时32例(80.0%)表现为重度至极重度感音神经性听力损失。
  • 携带至少一个N变异等位基因者听力水平显著优于双等位基因非N变异者(78.2 ± 23.9 dBHL vs 94.7 ± 22.8 dBHL,p = 0.033)。
  • 非极重度感音神经性听力损失患者中82.4%观察到进展性听力下降,平均进展速率为6.3 ± 4.8 dBHL/年,与基因型无关。
  • 25例接受人工耳蜗植入的患者中,大多数术后表现出良好的听觉和言语表现。

临床怎么用

  • 作者认为对双等位基因致病性MYO15A变异患者应进行定期听力监测,以实现早期干预。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Recessive variants in the MYO15A gene constitute an important cause of sensorineural hearing impairment (SNHI). However, the clinical features of MYO15A-related SNHI have not been systemically investigated. This study aimed to delineate the hearing features and outcomes in patients with pathogenic MYO15A variants. DESIGN: This study recruited 40 patients with biallelic MYO15A variants from 31 unrelated families. The patients were grouped based on the presence of N-terminal domain variants (N variants). The longitudinal audiological data and for those undergoing cochlear implantation, the auditory and speech performance with cochlear implants, were ascertained and compared between patients with different genotypes. RESULTS: At the first audiometric examination, 32 patients (80.0%) presented with severe to profound SNHI. Patients with at least one allele of the N variant exhibited significantly better hearing levels than those with biallelic non-N variants (78.2 ± 23.9 dBHL and 94.7 ± 22.8 dBHL, respectively) (p = 0.033). Progressive SNHI was observed in 82.4% of patients with non-profound SNHI, in whom the average progression rate of hearing loss was 6.3 ± 4.8 dBHL/year irrespective of the genotypes. Most of the 25 patients who underwent cochlear implantation exhibited favorable auditory and speech performances post-implantation. CONCLUSIONS: The hearing features of patients with biallelic pathogenic MYO15A variants are characterized by severe to profound SNHI, rapid hearing progression, and favorable outcomes with cochlear implants. Periodic auditory monitoring is warranted for these patients to enable early intervention.

来源:Ear Hear,查看原文。版权归原作者所有。

引用

  1. Chen PY, Tsai CY, Wu JL, et al. Hearing Features and Cochlear Implantation Outcomes in Patients With Pathogenic MYO15A Variants: a Multicenter Observational Study. Ear Hear. 2021. PMID: 34974475. doi:10.1097/AUD.0000000000001171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。